Skip to content
20-F

Annual Report (Foreign)

ProQR Therapeutics N.V. PRQR

0001104659-26-026713

← back to feed
Filed
Mar 12, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2025 · Dec 31, 2025 105.33M sh
Shares Diluted FY 2025 · Dec 31, 2024 86.09M sh
Shares Diluted FY 2025 · Dec 31, 2023 81.01M sh
Shares Outstanding FY 2025 · Dec 31, 2025 105.36M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −€52.79M
Operating Cash Flow FY 2025 · Dec 31, 2024 −€36.39M
Operating Cash Flow FY 2025 · Dec 31, 2023 €21.55M
Cash And Equivalents FY 2025 · Dec 31, 2025 €92.41M
Cash And Equivalents FY 2025 · Dec 31, 2024 €149.41M
Cash And Equivalents FY 2025 · Dec 31, 2023 €118.93M
Cash And Equivalents FY 2025 · Dec 31, 2022 €94.78M
Stockholders Equity FY 2025 · Dec 31, 2025 €49.37M
Stockholders Equity FY 2025 · Dec 31, 2024 €88.56M
Stockholders Equity FY 2025 · Dec 31, 2023 €41.39M
Stockholders Equity restated FY 2025 · Dec 31, 2022 €66.68M
Current Liabilities FY 2025 · Dec 31, 2025 €32.44M
Current Liabilities FY 2025 · Dec 31, 2024 €38.9M
Total Liabilities FY 2025 · Dec 31, 2025 €63.38M
Total Liabilities FY 2025 · Dec 31, 2024 €79.4M
Current Assets FY 2025 · Dec 31, 2025 €100.13M
Current Assets FY 2025 · Dec 31, 2024 €153.85M
Total Assets FY 2025 · Dec 31, 2025 €112.76M
Total Assets FY 2025 · Dec 31, 2024 €167.96M
Eps Diluted FY 2025 · Dec 31, 2025 −€0.40
Eps Diluted FY 2025 · Dec 31, 2024 −€0.32
Eps Diluted FY 2025 · Dec 31, 2023 −€0.35
Eps Basic FY 2025 · Dec 31, 2025 −€0.40
Eps Basic FY 2025 · Dec 31, 2024 −€0.32
Eps Basic FY 2025 · Dec 31, 2023 −€0.35
Rd Expense FY 2025 · Dec 31, 2025 €44.73M
Rd Expense FY 2025 · Dec 31, 2024 €36.36M
Rd Expense FY 2025 · Dec 31, 2023 €25.15M
Net Income FY 2025 · Dec 31, 2025 −€42.18M
Net Income FY 2025 · Dec 31, 2024 −€27.76M
Net Income FY 2025 · Dec 31, 2023 −€27.74M
Operating Income FY 2025 · Dec 31, 2025 −€43.45M
Operating Income FY 2025 · Dec 31, 2024 −€30.47M
Operating Income FY 2025 · Dec 31, 2023 −€31.86M